CJC-1295 Ipamorelin Dosage as Studied in the Research Literature

Read this first

This page logs CJC-1295 Ipamorelin dosage only as it appears in published studies — what researchers gave to people or animals, how, and for how long. It is not a protocol and not advice. There is no recommended human dose here, because neither peptide is approved and the fixed blend was never trialed. Numbers appear strictly as "studied at X µg/kg in [species] by [route]."

The headline to carry: the two halves last very different amounts of time. CJC-1295 with DAC stays active for days because it locks onto a blood protein; the no-DAC form and ipamorelin last minutes to a couple of hours. That mismatch is the single most important fact for understanding why a dosing schedule for one half does not transfer to the other.

Cjc 1295 ipamorelin dosage: the figures from the studies

The human cjc 1295 ipamorelin dosage figures come from the CJC-1295 side. In Phase 1 pharmacokinetic studies, CJC-1295 with DAC was given to healthy adults at 30 to 90 µg/kg subcutaneously, single and ascending doses ^[1][8]. At 60 or 90 µg/kg as a single subcutaneous injection, basal GH rose about 7.5-fold while pulsatility was preserved ^[8]. These were controlled research doses measured for pharmacokinetics — not a maintenance regimen and not transferable to community use.

For ipamorelin, the published doses are almost entirely from animal work: roughly 100 µg/kg three times daily in rodent bone studies, 0.5 mg/kg/day for bone mineral endpoints, and 0.01 to 1 mg/kg intravenously for gut-motility work, with around 1 µg/kg plateauing the GH response in rodent models. No validated human pharmacokinetic dose for ipamorelin has been published. There is no peer-reviewed human dosing study of the pre-mixed combination at all.

Cjc 1295 dac: why the DAC form is dosed less often

The cjc 1295 dac form is the long-acting one. DAC stands for Drug Affinity Complex: a chemical group on the peptide covalently bonds to Cys34 of serum albumin, a protein abundant in blood, turning the peptide into a slow-release depot. In rats this produced roughly a four-fold rise in GH area-under-the-curve and albumin-bound peptide detectable beyond 72 hours ^[5]; in humans a single dose sustained elevated GH for six or more days and IGF-1 for nine to eleven days ^[1]. Because the effect lasts days, research dosing of the DAC form is infrequent by design — its whole purpose is to avoid frequent injection. Its half-life in humans is on the order of six to eight days.

Mod grf 1-29: the short-acting, no-DAC counterpart

Mod grf 1-29 is CJC-1295 without DAC — the same modified GHRH(1-29) fragment, minus the albumin anchor. It produces a short, pulsatile GHRH signal rather than a multi-day plateau, with a half-life on the order of minutes to about 30 minutes, because dipeptidyl peptidase-IV rapidly cleaves GHRH-type peptides ^[14]. No formal standalone human pharmacokinetic study of Mod GRF (1-29) exists; research protocols have modelled it at roughly 100 to 200 µg per injection. The practical distinction: the DAC form gives a sustained background, while Mod GRF (1-29) gives a brief spike meant to mimic a natural GH burst. Confusing the two is the most common error in reading this literature, and it changes the entire exposure profile.

Routes, stability, and the human-data gap

Routes studied are subcutaneous and intravenous, plus continuous subcutaneous infusion by osmotic minipump and intranasal delivery in rodent pharmacokinetic work. On handling: lyophilised (freeze-dried) peptide is stable frozen for long periods; once reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide is kept refrigerated and degrades over weeks via asparagine deamidation, with degradation products markedly less potent. This is standard laboratory-handling context only.

The human-data gap is the headline limitation. CJC-1295 with DAC reached Phase 2 before development was discontinued; ipamorelin was investigated, including for postoperative ileus, but never approved. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination itself, so any "dose" for the blend is extrapolation from each component's separate literature plus general synergy data — not a studied figure.